MarketCap
Facebook
X
Telegram
Brickell Biotech Revenue | BBI
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Brickell Biotech
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.01 M | 6.94 M | 404 K | 1.82 M | 7.92 M | 124 K | 3.95 M | 14.5 M | 21 M | 15.2 M | 7.72 M | 17.5 M | 30 M | 8.71 M | 12.7 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 30 M | 124 K | 10.4 M |
Quarterly Revenue Brickell Biotech
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.94 M | 53 K | 9 K | - | 486 K | 4.32 M | 92 K | - | 132 K | 151 K | 17 K | - | 142 K | 607 K | 1.05 M | 669 K | 1.18 M | - | - | 124 K | 47 K | 735 K | 716 K | 3.95 M | 3.24 M | 3.42 M | 3.2 M | 3.16 M | 2.64 M | 4.12 M | 4.6 M | 6.81 M | 5.02 M | 4.18 M | 4.94 M | 4.82 M | 3.44 M | 4.5 M | 2.45 M | 3.14 M | 1.54 M | 1.46 M | 1.57 M | 2.32 M | 2.18 M | 1.56 M | 11.5 M | 1.93 M | 26.6 M | 818 K | 649 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 26.6 M | 9 K | 3.01 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
500 K | - | -6.63 % | $ 13.9 M |  USA |
 |
FSD Pharma
HUGE
|
257 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Qilian International Holding Group Limited
QLI
|
37.9 M | - | -6.08 % | $ 184 M |  China |
 |
Dynavax Technologies Corporation
DVAX
|
277 M | - | - | $ 2.02 B | USA |
 |
Assembly Biosciences
ASMB
|
72.3 M | $ 34.38 | 2.54 % | $ 385 M | USA |
 |
I-Mab
IMAB
|
27.6 M | - | - | $ 866 M | China |
 |
AgeX Therapeutics
AGE
|
130 K | - | -10.17 % | $ 12.2 K | USA |
 |
Axsome Therapeutics
AXSM
|
638 M | $ 207.77 | 0.53 % | $ 10.3 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Aytu BioScience
AYTU
|
66.4 M | $ 2.37 | 3.95 % | $ 14.9 M | USA |
 |
Happiness Biotech Group Limited
HAPP
|
14.6 M | - | 1.35 % | $ 17.8 M | China |
 |
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B |  France |
 |
BioLineRx Ltd.
BLRX
|
1.18 M | $ 2.81 | 1.81 % | $ 6.93 B |  Israel |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M |  Germany |
 |
BioMarin Pharmaceutical
BMRN
|
3.22 B | $ 66.7 | 0.14 % | $ 12.8 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Abcam plc
ABCM
|
362 M | - | - | $ 4.9 B |  Britain |
 |
Завод ДИОД
DIOD
|
517 M | - | - | - |  Russia |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M | Britain |
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M | Germany |
 |
BioXcel Therapeutics
BTAI
|
642 K | $ 0.8 | 0.66 % | $ 9.77 M | USA |
 |
Burford Capital Limited
BUR
|
413 M | $ 4.31 | 1.29 % | $ 945 M | Britain |
 |
Affimed N.V.
AFMD
|
8.28 M | - | -34.95 % | $ 21.5 M | Germany |
 |
Arcutis Biotherapeutics
ARQT
|
376 M | $ 25.08 | 1.12 % | $ 3.19 B | USA |
 |
Atara Biotherapeutics
ATRA
|
121 M | $ 9.7 | 3.41 % | $ 122 M | USA |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
12 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
5 K | - | - | $ 12.5 M |  Belgium |
 |
BeyondSpring
BYSI
|
1.35 M | $ 0.72 | 0.81 % | $ 29.6 M | USA |
 |
Generation Bio Co.
GBIO
|
19.9 M | - | - | $ 344 M | USA |
 |
Anika Therapeutics
ANIK
|
113 M | $ 21.78 | 2.06 % | $ 312 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
43 K | - | -4.36 % | $ 27 M | USA |
 |
GlycoMimetics
GLYC
|
10.8 M | - | 9357.83 % | $ 1.01 B | USA |
 |
AnaptysBio
ANAB
|
235 M | $ 57.74 | 1.85 % | $ 1.66 B | USA |
 |
Compugen Ltd.
CGEN
|
72.8 M | $ 2.62 | 0.19 % | $ 245 M | Israel |
 |
Aeterna Zentaris
AEZS
|
7.5 M | - | 5.93 % | $ 314 M | Canada |